<DOC>
	<DOCNO>NCT00646854</DOCNO>
	<brief_summary>The purpose study determine efficacy safety monoclonal antibody MabCampath® ( alemtuzumab ) combine chemotherapy treatment T-cell lymphoma .</brief_summary>
	<brief_title>Alemtuzumab CHOP T-cell Lymphoma</brief_title>
	<detailed_description>First International phase III T-cell lymphoma study Indication : Newly diagnose non-cutaneous peripheral T-cell lymphoma Study objective : Determination efficacy safety monoclonal antibody MabCampath® ( alemtuzumab ) combine two-weekly CHOP support G-CSF Primary Endpoint : Event-Free-Survival ( EFS ) Study Design : International open-label , multicentre , randomize Phase III Study Study Medication : Patients randomize six cycle two-weekly CHOP plus G-CSF without alemtuzumab give subcutaneously 30 mg day 1 combination chemotherapy cycle 1-4 . Patients CR , CRu PR 6 cycle CHOP14 combine alemtuzumab receive consolidation high-dose chemotherapy follow autologous stem cell transplantation . Patient Population : Patients &gt; 18 yr newly diagnose non-cutaneous , non-leukemic PTCL , except alk-protein positive negative anaplastic large cell lymphoma Planned Sample Size : 308 young patient ( 18-60 yr ) register randomized Total Number Centers : This study propose main European Australian Study Groups .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : Previously untreated patient newly diagnose peripheral Tcell lymphoma stage I bulk ( ≥ 7.5 cm ) stag II IV . Patients confirm histologic diagnosis peripheral Tcell NHL accord WHO classification : Peripheral Tcell lymphoma , unspecified ( PTCL NOS ) Angioimmunoblastic Tcell lymphoma Enteropathytype T cell lymphoma Subcutaneous panniculitislike TNHL ( gammadelta Tcell lymphoma ) Hepatosplenic Tcell lymphoma Extranodal NK/T cell lymphoma , nasal type Age 1860 year time randomization Life expectancy 3 month longer ECOG performance status ( PS ) 0 , 1 2 time randomization . However , PS 3 acceptable lymphomarelated . Measurable disease ( define least one lesion two measurable perpendicular diameter least one &gt; = 15 mm ) . Written informed consent Patients NK/TNHL follow type : Precursor T cell lymphoblastic lymphoma/leukemia All mature T cell leukemia ( TPLL , ATLL , NK cell leukemia , TLGL , HTLV1pos ATL ) Alkpositive negative anaplastic large cell lymphoma Blastic NK cell lymphoma Cutaneous Tcell lymphoma , transform Concurrent severe and/or uncontrolled medical disease ( e.g . uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month prior study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled infection ) , could compromise participation study . Known hypersensitivity murine chimeric antibody proteins Severe cardiac dysfunction ( NYHA classification IIIV , Appendix H ) LVEF &lt; 45 % Significant renal dysfunction , i.e . serum creatinin &gt; 2 time upper normal level ( UNL ) , unless relate NHL Significant hepatic dysfunction ( total bilirubin &gt; 2 time UNL transaminase &gt; = 2.5 time UNL ) , unless relate NHL Impaired pulmonary function ; case , patient exclude resultant pulmonary function test show FEV1 &lt; 50 % diffusion capacity &lt; 50 % reference value Suspected documented Central Nervous System involvement NHL Patients known HIVpositive Patients active , uncontrolled infection , especially know seropositivity HCV HbsAg Patients uncontrolled asthma allergy , require systemic steroid treatment Prior treatment chemotherapy , radiotherapy immunotherapy lymphoma , except local radiotherapy case extranodal NK/T cell lymphoma , nasal nasal type History active cancer past 5 year , except basal carcinoma skin stage 0 cervical carcinoma Unwillingness inability comply protocol Simultaneous participation study protocol Pregnant nursing woman ( Women childbearing potential use safe anticonceptives ) Contraceptive pill , intrauterine device , injection prolong gestagen , subdermal implantation , hormonal vaginal device transdermal patch consider safe contraceptive method ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Lymphoma , T-Cell</keyword>
	<keyword>Lymphoma , T-Cell , Peripheral</keyword>
	<keyword>MabCampath</keyword>
	<keyword>Campath</keyword>
	<keyword>CHOP-14</keyword>
	<keyword>CD52 expression</keyword>
</DOC>